leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...4546474849505152535455...235236»
  • ||||||||||  autogene cevumeran (RG6180) / Roche, Tecentriq (atezolizumab) / Roche
    Journal, Tumor-specific neoantigens, PD(L)-1 Biomarker, IO biomarker:  Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. (Pubmed Central) -  Jun 2, 2023   
    Triple-drug chemotherapy in a group of patients aged over 65 years with a diagnosis of advanced pancreatic cancer shows similar effectiveness to the general treated population, and with proper medical supervision the severity of side effects is at an acceptable level. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a
  • ||||||||||  Trial initiation date, Trial primary completion date, Real-world evidence:  CCGLC-001: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Jun 2, 2023   
    P=N/A,  N=300, Recruiting, 
    After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a Initiation date: Jan 2022 --> May 2020 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  lunresertib (RP-6306) / Repare Therap
    Enrollment open, Trial initiation date:  RP-6306 in Patients With Advanced Cancer (clinicaltrials.gov) -  May 31, 2023   
    P2,  N=78, Recruiting, 
    Phase classification: P1/2 --> P1 | N=19 --> 50 Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Apr 2023
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Monitoring physical impact and recovery of pancreatic cancer treatment using consumer wearable health data: A case report. (Pubmed Central) -  May 30, 2023   
    Treatment consisted of four courses of FOLFIRINOX neoadjuvant chemotherapy, a Whipple procedure with a right hemicolectomy and venous segment resection, and eight courses of adjuvant FOLFIRINOX chemotherapy...The physical impact of pancreatic cancer and its treatment and recovery was in this case reflected on consumer wearable health data. Seven months after the last chemotherapy recovery was close to baseline values.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Enrollment open, Trial initiation date, Trial primary completion date:  HLPDTLT: Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation (clinicaltrials.gov) -  May 30, 2023   
    P2,  N=59, Recruiting, 
    N=446 --> 186 Not yet recruiting --> Recruiting | Initiation date: Aug 2022 --> Aug 2023 | Trial primary completion date: Jul 2025 --> Aug 2027
  • ||||||||||  leucovorin calcium / Generic mfg.
    BRAT1 - clinical challenges as well as difficulties with genomic interpretation (Foyer 3B, 3rd Floor) -  May 29, 2023 - Abstract #EPNS2023EPNS_680;    
    Early and repeated video EEG is helpful to characterise the syndrome and differentiate from other myoclonic syndromes. Although biallelic variants presenting with RMFSL are likely to be life-limiting, care should be taken with genomic interpretation considering the milder BRAT1 disorder associated with non-progressive ataxia, intellectual disability and long life expectancy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Journal, Tumor microenvironment, IO biomarker:  The clinical relevance and prediction efficacy from therapy of tumor microenvironment related signature score in colorectal cancer. (Pubmed Central) -  May 26, 2023   
    Our findings suggested that the high TMERSS subtype may have a higher proportion of respondents to Cetuximab agent and immunotherapy, while the low TMERSS subtype may be more suitable for treatment with FOLFOX and FOLFIRI regimens. In conclusion, the TMERSS model may provide a partial reference for the prognosis evaluation of patients, the prediction of drug sensitivity, and the implementation of clinical decision-making.
  • ||||||||||  QL1203 / Qilu Pharma
    Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety (clinicaltrials.gov) -  May 26, 2023   
    P3,  N=590, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> Jul 2025 | Trial primary completion date: Oct 2022 --> Dec 2024
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Trial completion:  A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer (clinicaltrials.gov) -  May 25, 2023   
    P2,  N=180, Completed, 
    Trial completion date: Dec 2029 --> Mar 2030 | Trial primary completion date: Dec 2029 --> Mar 2030 Active, not recruiting --> Completed
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Journal, Surgery:  Late recurrent gastric carcinoma 12 (Pubmed Central) -  May 22, 2023   
    Consequently, CD44v9-positive gastric cancer grows in metastatic organs, repeatedly self-renews, and proliferates to form recurrent lesions. In the present case, the degree of CD44v9 staining in recurrent lesions was suggested to be related to the recurrence time.